Our research found an increased risk of vomiting and mucositis, which may indicate that in patients with UGT1A1 mutations, we should pay more attention to these two often overlooked adverse reactions related to CPT-11 use in daily clinical practice. Here, UGT1A1 is linked to mucositis.